211: Haploidentical Stem Cell Transplantation Using T- and B-Lymphocyte Depleted Grafts Following Reduced Intensity Conditioning for Wiskott-Aldrich Syndrome  by Kasow, K.A. et al.
78 Poster Session IObjective:Cord blood stem cells are routinely used in transplant
for hematological malignancies. Many nonmalignant disorders,
particularly genetic disorders, require allogeneic transplantation,
but autologous transplantation is also possible. This report docu-
ments 17 cord blood units (CBU) released by one bank for treat-
ment of nonmalignant hematopoietic disorders. Methods: Cord
blood was collected from the umbilical cord of consenting mothers
who elected to store CBU, however, directed donation was offered
to families with an individual diagnosed with a disease treatable with
stem cells. The whole blood product was processed at the Cord
Blood Registry laboratory in Tucson, AZ to separate mononuclear
cells (MNC) from red blood cells and non-engrafting cells. The
processed CBU were cryopreserved until requested for use. Prior
to release, viability and HLA were assessed.Results:Of 56 CBU re-
leased for transplant, 17 (30.4%) were for nonmalignant disorders: 3
thalassemia, 2 Fanconi anemia, 1 Hurler syndrome, 2 sickle cell ane-
mia, 6 aplastic anemia, 1 x-linked hyper IGM syndrome, 1 Diamond
Blackfan anemia, and 1 Wolman disease. 13 (76.5%) of 17 were
from a sibling, but 4 aplastic anemia transplants were autologous.
The 17 samples were stored a mean of 28.38 months (range: 2–
114), mean patient age was 5.4 years, and mean period of engraft-
ment was 18.94 days (range: 2–36), with a mean of 0.77%
CD341 cells. All units were viable for transplant. The patient
with Wolman disease died 17 days post-transplant due to unrelated
complications, engraftment was not evaluable. Conclusion: Cord
blood stem cells are increasingly common for patients with nonma-
lignant blood and marrow disorders, and the availability of sibling
cord blood decreases risk of transplant-related morbidity and mor-
tality. Nonmalignant disorders represent a third of all transplants
facilitated by this family bank, suggesting that they are a significant
indication for cord blood transplantation. Directed donation or pri-
vate banking should be considered for siblings of patients with
a nonmalignant disorder treatable with stem cells.
Recipient Time EngraftmentDiagnosis RDonor
elationshipAge
(yrs) (Stored
months)
time PMN .
500 (days) StatusBeta Thalassemia Sibling 3.3 5 17 CuredFanconi Anemia Sibling 5.0 12 24 CuredHurler Syndrome Sibling 2.6 2 12 Deceased -
organ failure;
cardiomyopathySickle Cell Anemia Sibling 9.8 29 23 CuredAplastic Anemia Auto 2.7 32 36 Deceased -
infection;
aspergillusSickle Cell Anemia Sibling 2.4 2 35 CuredBeta Thalassemia Sibling 7.1 5 13 CuredX-linked Hyper
IGM SyndromeSibling 3.1 7 14 UnknownFanconi Anemia Sibling 11.5 27 13 Deceased -
hemorrhage
post-liver biopsyAplastic Anemia Auto 3.0 36 2 RemissionAplastic Anemia Sibling 2.9 6 27 RemissionBeta Thalassemia Sibling 0.3 44 16 CuredAplastic Anemia Auto 4.9 58 29 RelapsedAplastic Anemia Auto 9.6 114 21 RemissionAplastic Anemia Sibling 5.3 24 7 RemissionDiamond Blackfan
AnemiaSibling 10.1 24 14 CuredWolman Disease Sibling 0.2 27 Unevaluable Deceased -
respiratory
failure210
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR HEMATOLOGIC MALIGNANCIES AFTER REDUCED INTENSITY CON-
DITIONING (RIC) IN CHILDREN AND YOUNG ADULTS
Duerst, R.E., Jacobsohn, D.A., Tse, W., Schneiderman, J., Kletzel, M.
Children’s Memorial Hospital, Feinberg School of Medicine, Northwest-
ern University, Chicago, IL.RIC regimens and allogeneic HSCT are used to treat adults with
malignancies, relying on cellular graft-vs-malignancy effects. Age or
co-morbid conditions do not preclude treatment. RIC regimens
could potentially reduce long-term morbidity, enhancing the qual-
ity of life in pediatric survivors of HSCT.
We report the experience of 44 RIC HSCT for children/young
adult patients (pts) with hematologic malignancies, 33 at high-risk
for complications of full-intensity conditioning due to disease state,
prior HSCT (5 allo, 7 auto) and/or co-morbidities. The RIC regi-
men was comprised of fludarabine, 150 mg/m2 over 5 days, followed
by IV busulfan, 0.8–1 mg/kg for 8 doses (n 5 14) or targeted AUC
4000 microMol*min for 2 doses (n5 30) and ATG. 10 pts received
extracorporeal photopheresis (ECP), and not ATG.
Diagnoses included: ALL (18,$CR3 in 9), AML (9, refractory in
3), CML (6), Non-Hodgkin’s Lymphoma (5), Hodgkin’s Lym-
phoma (2) or treatment-related myelodysplastic syndrome (4).
There were 26 males, 18 females, ages 2–21 yrs, median 11. Stem
cell sources included 22 unrelated donors (URD), 20 matched
sibs and 2 mis-matched relatives. 42 of 44 stem cell donations
were mobilized peripheral blood. Graft-versus-host disease
(GVHD) prophylaxis was cyclosporin A (CsA) alone in 11 pts,
CsA and mycophenolate (MMF) in 24 pts or CsA with MMF and
post-HSCT ECP in 9 patients.
The median time to reach an ANC.500/mcl was 19 days (range
9–62). An unsupported Plt Ct. 20,000/mcl was achieved in 40 pts
at a median of 17 days (7–228), 14 pts required no platelet support. 2
pts with URD failed to engraft and 2 had graft loss. 8 pts developed
Gr III-IV acute GVHD, 11 of the 34 pts surviving more than 100
days developed chronic GVHD (5 limited, 6 extensive). Sustained
full (.95%) donor chimerism was achieved in 24 pts.
13 pts survive without disease relapse or progression. 22 pts re-
lapsed or had molecular evidence of persistent disease. Of these, 3
pts are alive in subsequent remission following immune modula-
tion, 5 are in remission after further therapy (4 HSCT) and 5 con-
tinue therapy. 9 pts died after disease recurrence. Another 9 pts have
died, 7 from opportunistic infections, 2 from hyperacute GVHD.
Thus, the projected 3-year survival in this very high-risk group of
pts is 44%.
Our results suggest a graft vs malignancy effect can be harnessed
and RIC allogeneic HSCT should be considered for pediatric pts,
especially those at high-risk for complications after conventional
HSCT.211
HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING T- AND B-
LYMPHOCYTE DEPLETED GRAFTS FOLLOWING REDUCED INTENSITY
CONDITIONING FOR WISKOTT-ALDRICH SYNDROME
Kasow, K.A., Madden, R., Barfield, R., Leung, W., Hale, G.A. St. Jude
Children’s Research Hospital, Memphis, TN.
Wiskott - Aldrich syndrome (WAS) is a rare X-linked syndrome
characterized by micro- thrombocytopenia, eczema, and immuno-
deficiency, curable only through allogeneic hematopoietic stem
cell transplantation (HSCT). A mismatched family member is an
option when no matched related or unrelated donor is available.
Our team recently treated two young males, ages 1 year and 4 years,
who were enrolled on a prospective clinical trial using haploidenti-
cal HSCT for WAS. One donor was a 3/6 HLA-matched mother
and the other a 4/6-HLA matched father. A reduced intensity con-
ditioning (RIC) regimen consisting of fludarabine, thiotepa, mel-
phalan and OKT3 was administered. To reduce the risk of severe
graft-versus-host disease (GVHD) and EBV-lymphoma (PTLPD),
patients received a G-CSF mobilized peripheral blood stem cell
product depleted of T- and B-lymphocytes using the CliniMACS.
To facilitate engraftment, 1–2.5  105 CD31 cells/kg were added
to the graft. Cyclosporine was initiated on day -2 and continued un-
til day1100, then tapered in the absence of GVHD. The length of
hospitalization was 26 and 44 days. They received grafts containing
between 7.9–25.95  106 CD341 cells/kg and received 1.6–3.3 
104 CD191 cells/kg. Both demonstrated myeloid engraftment on
days 10 and 11 and achieved platelet engraftment of 50,000/mm3
by days 13 and 15. Only one patient, the one who received the lower
T-cell dose, experienced GHVD; he had grade 1 acute GHVD,
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developed EBV-PTLPD. CD31CD41 . 400/mm3 was achieved
by days1174 and1307, and each patient exhibited normal mitogen
responses to phytohemagglutinin and pokeweed by days 1275 and
1384. Vaccine responses to diphtheria and tetanus were noted in
the patient in whom titers were studied. There were no unexpected
toxicities related to the HSCT procedure, and both patients remain
alive greater than one year after HSCT with Lansky scores of 100.
Both are 100% donor chimerism by VNTR analysis, are transfusion
independent, had resolution of eczema, and have experienced com-
plete immune reconstitution. With these patients, we have demon-
strated that rapid hematopoietic engraftment and complete immune
reconstitution can be achieved with limited toxicity in patients with
WAS who receive a reduced intensity conditioning followed by a T-
and B-cell depleted haploidentical graft with specific T-cell add
back.212
SUCCESSFUL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR HIGH-RISK PAEDIATRIC ACUTE MYELOID LEUKAEMIA USING
CHEMOTHERAPY-ONLY CONDITIONING AND POST TRANSPLANT IM-
MUNOTHERAPY
Bonanomi, S.1, Connor, P.1, Webb, D.2, Ancliff, P.2, Persis, A.1, Rao, K.1,
McCloskey, D.3, Hemmatpour, S.3, Goulden, N.2, Veys, P.1. 1 Great
Ormond Street Hospital for Children, London, United Kingdom; 2 Great
Ormond Street Hospital for Children, London, United Kingdom; 3 Royal
London Hospital, London, United Kingdom.
Objectives: The role of allogeneic stem cell transplantation
(SCT) in paediatric acute myeloid leukaemia (AML) remains con-
troversial. SCT has generally been advocated for poor risk disease
in first complete remission (CR), the majority of patients following
relapse, and as a last resort in refractory disease. Methods: Twelve
consecutive patients (median age 2.2 years) underwent SCT for
high risk AML between 2000 and 2006. Patient and graft character-
istics are shown in the table.
Conditioning regimen consisted of busulphan (Bu) 16 mg/Kg,
cyclophosphamide (Cy) 120 mg/Kg, melphalan (Mel) 140 mg/m2;
alemtuzumab 1 mg/Kg was added in the unrelated donor setting.
Immunotheraputic strategies were employed to maximise a graft-
versus-leukaemia (GVL) response escalating through a reducedPatient
Age at
SCT
FAB
type Antecedent Cytogenetics
Disease
phase Donor type
GVHD
prophylaxis
1 2.0 M6 3q del, trisomy 21 CR1 MMUD alemtuzumab
CSA MTX
2 2.2 M7 complex CR1 MUD alemtuzumab
CSA MTX
3 1.7 M6 complex resistant
disease
MUD alemtuzumab
CSA MTX
4 2.7 M5 normal partial remission
after relapse
MMUD alemtuzumab
CSA MTX
5 1.6 M5 t(1;7)(q23;p22)
t(7;9;11)
CR2 MMUD alemtuzumab
CSA MTX
6 2.1 M0 t(7;12) CR2 MMUD alemtuzumab
CSA MTX
7 3.6 M7 normal partial remission
after relapse
MSD CSA
8 1.4 M0 normal partial remission
after relapse
MUD alemtuzumab
CSA MTX
9 5.7 secondary
AML
monosomy
7 trisomy 8
CR1 MMUD alemtuzumab
CSA MTX
10 2.4 M7 MDS monosomy 7 transformed
to AML
MSD CSA MTX
11 5.4 M2 MDS monosomy 7 transformed
to AML
MUD alemtuzumab
CSA MTX
12 2.2 M5 JMML del 9q transformed
to AML
MUD alemtuzumab
CSA MTXdose of alemtuzumab, early taper of cyclosporine A (CSA), donor
lymphocyte infusion (DLI) and treatment with alpha-interferon
(a-IFN). Results: All patients engrafted. Three out 5 patients un-
dergoing matched unrelated donor SCT, who were not in remis-
sion, received a 50% reduced dose of alemtuzumab. In 8 children
CSA was stopped early\ 2 months (n 5 4) and\ 3 months (n 5
4). Six of 12 patients developed acute graft versus host disease
(aGVHD), 3 grade 2, 3 grade 1. Five patients have developed lim-
ited chronic GVHD (cGVHD). In one patient who developed re-
cipient T-cell chimerism 2 months after SCT despite reduced
dose alemtuzumab and early taper of CSA, a DLI of 106/Kg was ad-
ministered followed by a-IFN. He developed grade 1 aGVHD and
the donor T cell chimerism increased to 80% but he never achieved
full donor haemopoiesis and relapsed 17 months after SCT. In an-
other patient, who developed no GVHD despite cessation of CSA at
day 32, a-IFN was administered: he developed grade 1 aGVHD
evolving to limited cGVHD and remains in remission at 9 months.
Ten of 12 (83%) patients are alive in CR at a median of 33 months
(range 9–80) from SCT. There was no transplant related mortality,
but two patients relapsed 3 and 17 months after SCT and subse-
quently died. Conclusion: This early promising data suggests
that the combination of Bu Cy Mel should be studied further as
a conditioning regimen in children with high risk AML. Given
the substantial risk of relapse, and in the absence of GVHD, this ap-
proach should be used as a platform for escalating immunothera-
peutic strategies with the endpoint of sustaining 100% donor
chimerism or achieving non severe GVHD to maximize the poten-
tial for a GVL effect.213
A NOVEL NON-MYELOABLATIVE CONDITIONING REGIMEN FOLLOWED
BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
PEDIATRIC PATIENTS WITH NON-MALIGNANT HEMATOLOGICAL DIS-
ORDERS
Hussein, A.A., Rihani, R., Rahman, F.A., Helalah, O.A., Taani, H.A.,
Nserat, T.A.L., Sarhan, M.M. King Hussein Cancer Center, Amman,
Jordan.
Purpose: To evaluate the efficacy of using a novel non-myeloa-
blative conditioning regimen followed by allogenic hematopoietic
stem cell transplantation (HSCT) for pediatric patients with non-
malignant hematological disorders.Paptients andMethods:Eight
patients less than 18 years of age with benign hematological diseases
and high risk features were transplanted from HLA identical related
donors between October, 2004 and August, 2007. Six patients had
sever thalassemia major, one patient had sickle cell anemia and
one had pure red cell aplasia. Seven were males and one female. Me-
dian age was 12 years (5–16). All patients had high serum ferritin
(1500–6000 ng/mL). All patients had significant palpable hepato-
megaly (4–8 cm). Four patients had hepatitis C infection, 6 patients
had grade II-III hepatic fibrosis on liver biopsy and one patient had
uncontrolled Nephrotic syndrome.
All patients received non-ablative conditioning regimen con-
sisted of: Busulphan (2 mg/kg twice daily for two days), Fludarabine
(35 mg/m2/day for 5 days), Horse ATG (30 mg/kg/day for 5 days)
and total lymphoid irradiation (500 cGy on Day zero). Cyclosporine
and oral Mycophenolate Mofetil were used as Graft versus Host
Disease (GvHD) prophylaxis. Six patients received mobilized pe-
ripheral stem cells while two patients received G-CSF primed
bone marrow cells. Results: After a median follow up of 13 months
(2–36), all patients are alive and doing well with no blood transfu-
sion requirement. Mean CD34 graft dose was 4.4 106/kg. All pa-
tients showed primary neutrophil engraftment at a median of 19
days (12–24). Four patients have sustained full donor chimerim,
while 3 patients have stable mixed donor chimerism (52–94%),
only one patient had graft failure 10 months after HSCT and he
is now doing well with full donor chimerism 20 months following
second non-ablative transplantation.
No patient required ICU admission post transplantation. Four
patients developed acute veno-oclusive disorder within first 30
days after HSCT; all were salvaged with supportive treatment.
Three patients had Grade II-III acute GvHD. Two patients had
Grade I-II chronic GvHD. Two patients developed posterior
